不同剂量他汀治疗AMI临床效果及其对患者炎症因子hs-CRP、IL-6的影响
Clinical effects and impacts on hs-CRP, IL-6 of different dose of statins on AMI patients

陈美英.不同剂量他汀治疗AMI临床效果及其对患者炎症因子hs-CRP、IL-6的影响[J].内科急危重症杂志,2017,23(2):

扫码阅读全文

DOI：

中文关键词: 不同剂量他汀 hs-CRP IL-6

英文关键词:

基金项目:

作者	单位	E-mail
陈美英	广东省水电医院	chenmeishuang197@163.com

摘要点击次数: 3002

全文下载次数: 4019

中文摘要:

【】目的：探讨不同剂量的他汀对急性心肌梗死(acute myodial infarction, AMI)患者临床效果的影响,并分析对炎症因子超敏C-反应蛋白(high sensitivity C-reactive protein, hs-CRP)、白介素-6(interleukin 6, IL-6)等的影响。方法选取我院2013年8月至2015年9月收治的90例AMI患者,均行经皮冠状动脉介入术(PCI)治疗,随机分为两组,低剂量组45例,口服瑞舒伐他汀10mg,高剂量组45例,口服瑞舒伐他丁20mg,每晚各一次。入院后、治疗后4周分别检测生化指标、血流动力学等心功能指标比较两组患者的临床治疗效果,并比较两组患者入院后、治疗后4周hs-CRP、IL-6等炎症指标。结果治疗后4周,高剂量组BNP(4.82±1.63)ng/l,TC(4.20±0.92)mmol/l,LDL-C(1.63±0.53)mmol/l,LVEDD(46.78±3.21)mm, LVESD(30.72±4.01)mm,均显著低于低剂量组,LVEF(52.75±3.36)%高于低剂量组,差异具有统计学意义(P<0.05)；治疗后4注,高剂量组hs-CRP(3.06±1.32)mg/l,IL-6(17.87±3.03)ng/l,均较低剂量组低,高剂量组hs-CRP变化值(4.03±0.95)mg/l,IL-6变化值(13.83±3.24)ng/l,均高于低剂量组,组间比较具有统计学差异(P<0.05)。结论采用大剂量瑞舒伐他汀治疗AMI能显著改善患者心功能,降低hs-CRP、IL-6水平,减轻炎症反应。

英文摘要:

［］Objective: To discuss the clinical effects of different dose of statins on acute myocardial infarction patients, and analysis impacts on hs-CRP, IL-6. Method:A number of 90 patients withacute myocardial infarction in our hospital from August 2013 to September 2015, which were all treated with percutaneous coronary intervention, were divided into two groups according to treatments: the primary group(n=38) with primary PCI treatment; the low dose group(n=45) with 10mg rosuvastatintreatment; the high dose group(n=36) with 20mg rosuvastatin treatment. The biochemical parameters and hemodynamics indexes of all patients in pre-treatment and 4 weeks after treatment were detected and compared, and hs-CRP, IL-6of two groups in pre-treatment and 4 weeks after treatment were evaluated. Result: In 4 weeks after treatment, theBNP(4.82±1.63)ng/l,TC(4.20±0.92)mmol/l,LDL-C(1.63±0.53)mmol/l,LVEDD(46.78±3.21)mm, LVESD(30.72±4.01)mm ofhigh dose group were significantly lower then these of low dose group,LVEF(52.75±3.36)% of high dose group were remarkably higher then that of low dose group, P<0.05; In 4 weeks after treatment,hs-CRP(3.06±1.32)mg/l,IL-6(17.87±3.03)ng/lof high dose group were markedly lower then these of low dose group, the change of hs-CRP(4.03±0.95)mg/l, the change of IL-6(13.83±3.24)ng/l were evidently higher then these of low dose group, P<0.05. Conclusion: High dose of rosuvastatin can evidently improve heart function of AMI, decrease the levels of hs-CRP and IL-6, and reduce inflammatory reaction.